Investors Research Corp’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Investors Research Corp’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,000	Closed	-$30K	–	1154
2020 Q1	$30K	Hold	1,000	–	–	0.02%	537
2019 Q4	$36K	Hold	1,000	–	–	0.02%	574
2019 Q3	$27K	Hold	1,000	–	–	0.01%	632
2019 Q2	$24K	Hold	1,000	–	–	0.01%	654
2019 Q1	$26K	Sell	1,000 -10,900	-92%	-$258K	0.01%	620
2018 Q4	$233K	Hold	11,900	–	–	0.16%	221
2018 Q3	$233K	Hold	11,900	–	–	0.13%	259
2018 Q2	$197K	Hold	11,900	–	–	0.11%	289
2018 Q1	$169K	Hold	11,900	–	–	0.1%	290
2017 Q4	$174K	Buy	+11,900	New	+$167K	0.11%	290

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Investors Research Corp's HZNP Position: Q2 2020 in Review

Investors Research Corp sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2020, closing a stake of 1,000 shares — an estimated $30K sold.

Investors Research Corp first reported a position in HZNP in Q4 2017 and held it in 10 quarters. The position peaked at $233K in Q4 2018. 354 funds tracked by Wall St. Rank hold HZNP as of Q2 2020.

Investors Research Corp reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2020 after selling out during the quarter.
Investors Research Corp sold 1,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2020, an estimated $30K.
Investors Research Corp first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 10 quarters.
Investors Research Corp's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $233K in Q4 2018.
354 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2020.

Based on Investors Research Corp's 13F filing for Q2 2020, filed 21 Jul 2020.